TCTA (T cell leukemia translocation altered) encodes a small 12,000 Da protein that plays a regulatory role in osteoclast biology and has clinical significance in hematological malignancies. The gene was originally identified at a t(1;3) translocation breakpoint in T-cell acute lymphoblastic leukemia and is ubiquitously expressed in normal tissues, with highest expression in kidney 1. TCTA's primary function involves negative regulation of osteoclastogenesis through inhibition of cellular fusion during osteoclast formation 2. Mechanistically, peptides derived from TCTA's extracellular domain, particularly those containing the GQN sequence, prevent cellular fusion by interacting with putative counterpart molecules, thereby suppressing the formation of large multinucleated osteoclasts without affecting NFATc1 expression 2. In disease contexts, TCTA shows reduced expression in small cell lung cancer cell lines, suggesting potential tumor suppressor activity 1. Recent studies demonstrate that high TCTA expression correlates with poor prognosis in acute myeloid leukemia, with involvement in critical pathways including hematopoiesis, p53 signaling, and DNA methylation 3. Clinically, TCTA represents a promising prognostic biomarker in AML and a potential therapeutic target for bone resorption disorders.